IGM Biosciences Management
Management criteria checks 2/4
IGM Biosciences' CEO is Mary Harler, appointed in Oct 2024, has a tenure of less than a year. directly owns 0.58% of the company’s shares, worth $2.36M. The average tenure of the management team and the board of directors is 3.1 years and 6.2 years respectively.
Key information
Mary Harler
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.6% |
| Management average tenure | 3.1yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Oct 08
IGM Biosciences: Waiting For Godot
Sep 18IGM Biosciences: Unlikely To Move The Needle Again In 2024
May 12Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?
Apr 28IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25CEO
Mary Harler (59 yo)
less than a year
Tenure
Ms. Mary Beth Harler, M.D. is the Chief Executive Officer of IGM Biosciences, Inc. since October 01, 2024 and serves as its Director. She had been Head of Research & Autoimmunity at IGM Biosciences, Inc. s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | 0.58% $ 2.4m | |
| Chief Financial Officer | 6yrs | US$1.08m | 0.037% $ 150.5k | |
| Senior Vice President of Group Operations | 2yrs | no data | no data | |
| Senior VP | 2.8yrs | no data | 0.0054% $ 21.8k | |
| Senior Vice President of Legal Affairs | 4yrs | no data | no data | |
| Chief Human Resources Officer | 5.6yrs | no data | no data | |
| Executive Vice President of Research | 3.4yrs | no data | no data | |
| Chief Business Officer | 3.8yrs | US$4.92m | 0.032% $ 127.5k | |
| Executive Vice President of Process Development & Manufacturing | 3.8yrs | no data | no data | |
| Senior Vice President of Intellectual Property | 2.8yrs | no data | no data | |
| Senior Vice President of Quality | 2yrs | no data | no data | |
| Senior Vice President of Manufacturing Operations | 1.4yrs | no data | no data |
3.1yrs
Average Tenure
55yo
Average Age
Experienced Management: IGMS's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | no data | 0.58% $ 2.4m | |
| Independent Director | 4yrs | US$168.55k | 0.0037% $ 15.1k | |
| Independent Director | 6yrs | US$178.30k | 0.69% $ 2.8m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.5yrs | US$166.09k | 0.019% $ 75.2k | |
| Independent Director | 6.4yrs | US$166.09k | 0.15% $ 612.4k | |
| Independent Director | 6.4yrs | US$204.09k | 0.0034% $ 13.6k | |
| Independent Director | 6.4yrs | US$175.84k | 0.10% $ 418.0k | |
| Independent Director | 6.4yrs | US$236.59k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$167.54k | 0.0098% $ 39.5k | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.2yrs
Average Tenure
55yo
Average Age
Experienced Board: IGMS's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 23:13 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IGM Biosciences, Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | BMO Capital Markets Equity Research |
| Geoffrey Meacham | BofA Global Research |
| Charlie Yang | BofA Global Research |